RxDoctor Payments Data

Megan Ricard

Family · Nashua, NHNPI 1215438304

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,522 of the $7,226 with a category attached, or 62.6%. Boston Scientific accounts for 82.6% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $2,944 and has fallen 63.1% since, to $1,087 in 2025. Among family clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,226in general payments, 2019–2025

Across 122 payments — averaging $59.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$6K
  • Collegium Pharmaceutical, Inc.$252
  • Johnson & Johnson$245
  • AbbVie$224
  • SPR Therapeutics, Inc$205
  • Painteq LLC$98
  • plus $237 from 7 others

What the payments were for

  • Travel & lodging$2,70437%
  • Food & beverage$4,52263%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,226 in reported general payments places this provider in the 95th percentile of 713 family providers in New Hampshire.

See all family providers in New Hampshire

Medicare billing

Part B allowed, 2024
$63,086
Medicare patients
240
Services billed
570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate15$8,489
Nucynta ErTapentadol Hcl11$6,890
OxycontinOxycodone Hcl16$5,984
Oxycodone Hcl145$5,146
SuboxoneBuprenorphine Hcl/Naloxone Hcl11$3,177
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl50$2,871
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen71$1,438
Gabapentin104$1,397
Pregabalin56$1,304
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen65$1,303
Lidocaine28$1,218
Morphine Sulfate ErMorphine Sulfate13$1,003
Doxepin Hcl12$560
Methocarbamol33$478
Celecoxib20$409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er$252$15,37926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 713 family providers in New Hampshire.

Other family in Nashua

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →